CD40L and IL-2 gene-modified autologous fibroblasts and leukemic blasts (Dose Level 3)

Dose Level 3-Baylor College of Medicine-leukemia-myelodysplastic syndrome refers to a specific cohort in a Phase 1 clinical trial (NCT00020449) evaluating an autologous cancer vaccine for high-risk acute leukemia and myelodysplastic syndrome. The therapeutic approach involves collecting a patient's skin fibroblasts via punch biopsy and transducing them with adenoviral vectors to express human CD40 ligand (CD40L) and interleukin-2 (IL-2). These modified fibroblasts are then mixed with the patient's own leukemic blasts and administered to the patient, typically via subcutaneous injection. CD40L acts as a potent costimulatory molecule that activates antigen-presenting cells, while IL-2 serves as a T-cell growth factor to enhance the systemic anti-leukemic immune response. Dose Level 3 specifically utilizes a formulation containing 2 x 10^7 leukemic blasts, 2 x 10^7 IL-2-expressing fibroblasts, and 4.2 x 10^7 CD40L-expressing fibroblasts. The study was conducted by Baylor College of Medicine but was terminated due to slow patient accrual.

Other names

Dose Level 3-Baylor College of Medicine-leukemia-myelodysplastic syndromeAd-hCD40L/Ad-hIL-2 modified fibroblasts vaccineCD40L and IL-2 gene-modified autologous fibroblasts and tumor cellsCD-40L and IL-2 gene-modified autologous fibroblasts and tumor cellsCD 40L and IL-2 gene-modified autologous fibroblasts and tumor cellsCD40L and IL-2 gene-modified autologous skin fibroblasts mixed with leukemic blastsCD-40L and IL-2 gene-modified autologous skin fibroblasts mixed with leukemic blastsCD 40L and IL-2 gene-modified autologous skin fibroblasts mixed with leukemic blasts